FDA Approves First Generic of Climara Pro, a Once-Weekly Estradiol and Levonorgestrel Patch
Last updated 2026-10-31 · Source: FDA press release, October 20, 2026
Primary source: FDA press release, October 20, 2026: FDA Approves First Generic of Climara Pro, a Once-Weekly Estradiol and Levonorgestrel Patch
On October 19, 2026, FDA approved the first generic of Climara Pro, Zydus's once-weekly estradiol and levonorgestrel patch for women with an intact uterus.
What this means for your practice
This approval signifies increased access to an affordable and convenient treatment option for menopausal hormone therapy. For telehealth providers, this means a wider range of therapeutically equivalent, cost-effective medications can be prescribed, potentially improving patient adherence due to the once-weekly dosing schedule and patch format. Practices managing women's health will find this generic particularly useful for patients with an intact uterus, given its combined estrogen and progestogen formulation that mitigates endometrial hyperplasia risk. While directly impacting medical and women's health specialties, the broader implication for all healthcare businesses is the FDA's continued commitment to expanding the availability of generic drugs to lower healthcare costs and improve patient access, a trend that encourages comprehensive care planning and patient education regarding treatment options.
On October 19, 2026, the Food and Drug Administration (FDA) approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a hormone therapy patch applied once a week by women with an intact uterus. FDA announced the approval in a press release on October 20. The approved generic is Zydus Pharmaceuticals (USA) Inc.'s Estradiol and Levonorgestrel Transdermal System.
What was approved
FDA says the generic is therapeutically equivalent to Climara Pro, which is indicated for women with an intact uterus for:
- treatment of moderate to severe vasomotor symptoms due to menopause, and
- prevention of postmenopausal osteoporosis.
Climara Pro and the generic contain both an estrogen and a progestogen in one patch, unlike the estrogen-only patches commonly used in menopause treatment. FDA explains that the progestogen is included to reduce the risk of endometrial hyperplasia that can occur with estrogen alone.
Acting FDA Commissioner Kyle Diamantas, J.D., said: "Menopause is a universal experience for women, and it can greatly affect a person's quality of life. This approval makes effective treatment more accessible." Michael Davis, M.D., Ph.D., Director of FDA's Center for Drug Evaluation and Research, said: "Once-weekly dosing can make a real difference in how patients manage their care. A patch offers a convenient alternative to daily oral medications, which may help patients stay on track with their treatment."
Contraindications and common adverse reactions
FDA lists these contraindications for Climara Pro and the generic: undiagnosed abnormal genital bleeding; breast cancer or a history of breast cancer; estrogen-dependent neoplasia; active deep vein thrombosis or pulmonary embolism, or a history of them; active arterial thromboembolic disease or a history of it; known anaphylactic reaction, angioedema or hypersensitivity to estradiol and levonorgestrel; hepatic impairment or disease; and protein C, protein S or antithrombin deficiency, or other thrombophilic disorders.
The most common adverse reactions (5% or more) are application site reaction, vaginal bleeding, breast pain, upper respiratory infection, back pain, depression, pain, headache and flu syndrome.
What this means for menopause telehealth programs
- A new combined option for patients with a uterus. Programs that prescribe menopausal hormone therapy now have a generic, FDA-approved, once-weekly combined estrogen and progestogen patch to consider alongside the brand.
- Screen for every listed contraindication. Intake and follow-up forms should capture each contraindication above, including clotting history and thrombophilic disorders, before a patch is prescribed.
- Check availability before you build it in. FDA tells prescribers to contact the manufacturer about availability, so confirm supply with your pharmacy partners before adding the generic to a protocol.
Key facts
| Detail | Value |
|---|---|
| Approval date | October 19, 2026 (announced October 20, 2026) |
| Generic | Estradiol and Levonorgestrel Transdermal System, 0.045 mg per day/0.015 mg |
| Reference brand | Climara Pro (a registered trademark of Bayer) |
| Generic manufacturer | Zydus Pharmaceuticals (USA) Inc. |
| Dosing | One patch applied once a week |
| Indications | Moderate to severe vasomotor symptoms due to menopause; prevention of postmenopausal osteoporosis (women with an intact uterus) |
Frequently asked questions
Who makes the generic?
Zydus Pharmaceuticals (USA) Inc.
Who is it for?
Women with an intact uterus, for moderate to severe vasomotor symptoms due to menopause and for prevention of postmenopausal osteoporosis.
Why does it contain a progestogen?
FDA says the progestogen is included to reduce the risk of endometrial hyperplasia that can occur with estrogen use alone.
Source: FDA: FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women · October 20, 2026